Adapt and Evaluate MARVIN Chatbots Using Artificial Intelligence to Provide Health Information for HIV, Breast Cancer, Pediatric Infectious Conditions, and Pharmacists
Led by McGill University Health Centre/Research Institute of the McGill University Health Centre · Updated on 2024-03-06
400
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a master research protocol to adapt and evaluate the MARVIN chatbot, an artificial intelligence-based conversational agent, for providing information across different health conditions such as HIV infections, breast cancer, and pediatric infectious conditions. This study uses an adaptive platform trial design to allow multiple chatbot interventions tailored to various populations, enabling early withdrawal of ineffective arms and introduction of new ones. The goal is to develop, adapt, and assess the usability and implementation outcomes of these chatbots through co-construction with participants and research teams.
The study involves four chatbot interventions delivered via Meta Facebook Messenger MARVIN for HIV patients, MARVIN-Pharma for community pharmacists, MARVINA for breast cancer patients, and MARVIN-CHAMP for pediatric patients with infectious conditions. Participants will be involved in co-constructing the chatbots, usability studies, implementation, evaluation of outcomes, and continuous improvements. This ongoing process allows the chatbots to be progressively refined to meet the needs of each user group.
Participants aged 14 and older who understand the study requirements and have access to a smartphone, tablet, or computer with internet or data plan will engage with the chatbots over time. Researchers will assess usability using tools like the Usability Metric for User eXperience UMUX-Lite and Acceptability E-Scale AES immediately and at intervals over 12 months. They will also evaluate implementation outcomes such as intervention appropriateness and compatibility. Throughout the study, participants interaction with the chatbots and their experience will be continuously monitored and improved.
CONDITIONS
Brief Title
The MARVIN Chatbots to Provide Information for Different Health Conditions
Research Team
B
Bertrand Lebouché, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborating Sponsor
Who Can Participate
Age: 14Years +
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
14 years of age or older
Fluent in English and/or French
Able to understand study requirements and provide informed consent
Have access to a smartphone, tablet, or computer at home or workplace
Have internet access or a data plan on their device
Willing to use a Facebook Messenger-based chatbot
Agree to use or create a personal Facebook account
Accept Facebook's privacy and data security policies
You will not qualify if you...
Not meeting all inclusion criteria
Any condition judged by the investigator that makes participation inappropriate, such as cognitive deficits
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) to confirm eligibility and provide informed consent
Co-construction and Usability Testing
Duration - 1 month
Participants collaborate in adapting the chatbot and evaluate its usability in their specific healthcare context.
Initial baseline visit followed by usage over 1 month with remote check-ins
Implementation and Outcome Evaluation
Duration - Up to 12 months
Participants use the chatbot over time while researchers evaluate implementation fidelity and user outcomes such as acceptability and appropriateness.
Quarterly visits (every 3 months) for assessments over 12 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
4
Similar Trials
Studying Key Non-coding RNAs and Their Interaction With Chromatin Remodeling in Breast Cancer Patients
Comparing 18F-FDG and 68Ga-FAPI-46 PET Scans in Women With ER-positive Breast Cancer
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Observational Study Comparing 3D and 2D Echocardiography for Early Heart Damage Detection in Patients Receiving Anthracyclines and HER2-Targeted Cancer Therapies
Study Comparing 3D-Printed Biodegradable Breast Implants, Traditional Breast-Conserving Surgery, and Silicone Implant Reconstruction for Breast Cancer Patients
Ultrahypofractionated 5-Session Whole Breast Radiotherapy with Boost versus Standard 15-Session Radiotherapy for Breast Cancer Patients with Unfavorable Characteristics
Phase II Study Comparing 5-Day vs. 9-Day Whole Breast Radiotherapy with Boost in Early-stage Breast Cancer
Evaluating 68Ga-FAPI PETCT for Checking Axillary Lymph Node Status After Neoadjuvant Therapy in Women with Breast Cancer
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors
Exploratory Study of 68Ga-SorB PETCT Imaging to Diagnose Sortilin-Positive Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Adapting and Evaluating an AI-Based Chatbot Through Patient and Stakeholder Engagement to Provide Information for Different Health Conditions: Master Protocol for an Adaptive Platform Trial (the MARVIN Chatbots Study).